Summary
PathAI and Discovery Life Sciences have partnered to deploy AI-powered pathology solutions, providing enhanced digital insights from biospecimens to accelerate drug development and diagnostics.
Key Takeaways
- AI Integration in Pathology: Discovery will globally implement PathAI’s solutions, automating routine tasks and enhancing pathology assessments with quantitative tissue insights.
- Advancing Drug Development: The partnership aims to develop custom AI-driven tissue analysis panels to support biomarker discovery and translational research for biopharma partners.
- Precision Medicine Focus: The collaboration addresses the growing demand for precision diagnostic tools, crucial for optimizing patient selection in immuno-oncology and other therapeutic areas.
PathAI, a provider of AI-powered pathology technology, today announced a strategic partnership with Discovery Life Sciences, a leading biospecimens and specialty lab testing company, to offer Discovery’s customers enhanced, AI-enabled digital and quantitative insights from biospecimens to better inform drug and diagnostic development. This collaboration marks a milestone as the first at-scale deployment of AI technologies into a leading commercial biobank.
“We are excited to partner with Discovery Life Sciences to revolutionize the biospecimens industry,” says Andy Beck, CEO of PathAI. “Our digital pathology solutions will enable Discovery Life Sciences to provide unparalleled accuracy and speed in pathology assessments, ultimately benefiting their customers with enhanced data quality and insights and accelerating the discovery and development of new therapies and diagnostics.”
AI-Powered Pathology Readied for Global Launch
Through this partnership, Discovery will deploy PathAI’s AISight Image Management System (IMS), ArtifactDetect, and TumorDetect products globally across its biospecimens business. In doing so, Discovery will help transform their traditional pathology workflow, significantly saving pathologists’ time by automating routine tasks and analysis and allowing pathologists to focus on more complex tasks. Discovery will also empower customers with additional quantitative, tissue-level insights to provide more confident and standardized structured data from their biospecimens.
Building on this deployment, the companies will collaborate to develop a custom AI-driven tissue analysis panel exclusive to Discovery, further advancing translational research and biomarker discovery for biopharma partners. Looking beyond applications within Discovery’s biospecimens business, this partnership will allow for further exploration within Discovery’s Specialty Lab Services business, leveraging AI-powered pathology technology solutions to deliver deeper insights to accelerate drug development and precision medicine initiatives.
“Integrating PathAI’s advanced AI technology aligns perfectly with our commitment to providing our customers with the highest quality and most comprehensive data and insights from their biospecimens investment,” said Greg Herrema, CEO of Discovery. “This partnership will significantly enhance our ability to deliver precise, reliable, and timely insights, ultimately advancing the discovery and development of therapies and diagnostics that improve patient outcomes.”
Need for Precision Diagnostics Increasing
As investments in immuno-oncology and antibody-drug conjugates continue to rise, the need for precision diagnostic tools that optimize patient selection will become more critical. The combination of PathAI’s AI-powered pathology products and Discovery’s high-quality, structured, multi-modal datasets will catalyze the development of new assays and diagnostic tools more reliably and quickly with the objective of enabling improved patient outcomes.
Featured Photo: Anatolii Savitskii | Dreamstime.com
